Modulation of the Aβ peptide aggregation pathway by KP1019 limits Aβ-associated neurotoxicity
The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that is increasing worldwide due to increased life expectancy. AD is characterized by two pathological hallmarks in the brain: amyloid-β (Aβ) plaque deposits and neurofibrillary tangles. A focus of AD research has concentrated on either inhibiting Aβ peptide aggregation that leads to plaque formation or breaking down pre-formed Aβ peptide aggregates. An alternative approach is to modulate the Aβ aggregation profile by facilitating the formation of Aβ species that are off-pathway and non-toxic. Herein, we report the re-purposing of the widely studied Ru(iii) anti-cancer complex KP1019, towards regulating the aggregation profile of the Aβ peptide. Using electron paramagnetic resonance (EPR) spectroscopy, we conclude that KP1019 binds to histidine residues, located at the N-terminus of the peptide, in a rapid and robust fashion. Native gels and transmission electron microscopy (TEM) analyses have provided insight into the species and structures that are generated by KP1019-Aβ interactions. Finally, incubation in an in vitro human neuronal cell model has demonstrated that the formation of KP1019-Aβ species rescues cell viability from Aβ-associated neurotoxicity. Modulation of the Aβ aggregation pathway via covalent interactions with small molecules is thus a promising AD therapeutic strategy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A widely studied Ru(III) anticancer drug, KP1019 (60), reveals a unique anti-Aβ strategy. Unlike conventional methods that inhibit Aβ production and aggregation, KP1019 (60) counteracted Aβ toxicity to neuronal cell models by promoting the formation of soluble high-molecular-weight Aβ aggregates.568”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [568]
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., & Stefani, M. (2002) · Nature · doi:10.1038/416507a · Cited by 2,434
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Alzheimer's disease: strategies for disease modification
Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,064
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity
Bieschke, J., Russ, J., Friedrich, R. P., Ehrnhoefer, D. E., Wobst, H., Neugebauer, K., & Wanker, E. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910723107 · Cited by 1,011
Calcium dyshomeostasis and intracellular signalling in alzheimer's disease
LaFerla, F. M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn960 · Cited by 978
Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
Structural Classification of Toxic Amyloid Oligomers
Glabe, C. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800016200 · Cited by 783
Structure–neurotoxicity relationships of amyloid β-protein oligomers
Ono, K., Condron, M. M., & Teplow, D. B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905127106 · Cited by 770
Necula, M., Kayed, R., Milton, S., & Glabe, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608207200 · Cited by 680
Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Bioinorganic Chemistry of Alzheimer’s Disease
Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 672
Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637
Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers‐Nolten, I., Van Der Werf, K., Subramaniam, V., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.211 · Cited by 532
Approaching tumour therapy beyond platinum drugs
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.09.030 · Cited by 514
Resolving controversies on the path to Alzheimer's therapeutics
Selkoe, D. J. (2011) · Nature Medicine · doi:10.1038/nm.2460 · Cited by 494
Small-molecule conversion of toxic oligomers to nontoxic β-sheet–rich amyloid fibrils
Bieschke, J., Herbst, M., Wiglenda, T., Friedrich, R. P., Boeddrich, A., Schiele, F., Kleckers, D., Lopez del Amo, J. M., Grüning, B. A., Wang, Q., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.719 · Cited by 445
Disaggregation of Alzheimer β-amyloid by site-directed mAb
Solomon, B., Koppel, R., Frankel, D., & Hanan-Aharon, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4109 · Cited by 421
Ruthenium metallopharmaceuticals
Clarke, M. J. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00025-5 · Cited by 396
Misfolded proteins in Alzheimer's disease and type II diabetes
DeToma, A. S., Salamekh, S., Ramamoorthy, A., & Lim, M. H. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15112f · Cited by 361
Role of Metal Ions in the Self-assembly of the Alzheimer’s Amyloid-β Peptide
Faller, P., Hureau, C., & Berthoumieu, O. (2013) · Inorganic Chemistry · doi:10.1021/ic4003059 · Cited by 353
Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer
Kayed, R., Pensalfini, A., Margol, L., Sokolov, Y., Sarsoza, F., Head, E., Hall, J., & Glabe, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808591200 · Cited by 348
Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42
LIU, R., BARKHORDARIAN, H., EMADI, S., PARK, C., & SIERKS, M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.02.003 · Cited by 339
Protein-induced photophysical changes to the amyloid indicator dye thioflavin T
Wolfe, L. S., Calabrese, M. F., Nath, A., Blaho, D. V., Miranker, A. D., & Xiong, Y. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002867107 · Cited by 329
Reedijk, B. J. (2008) · Platinum Metals Review · doi:10.1595/147106708x255987 · Cited by 312
Toxic fibrillar oligomers of amyloid-β have cross-β structure
Stroud, J. C., Liu, C., Teng, P. K., & Eisenberg, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203193109 · Cited by 303
Amyloid β-protein oligomers and Alzheimer’s disease
Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt226 · Cited by 276
Lentz, F., Drescher, A., Lindauer, A., Henke, M., Hilger, R. A., Hartinger, C. G., Scheulen, M. E., Dittrich, C., Keppler, B. K., & Jaehde, U. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328322fbc5 · Cited by 239
Nie, Q., Du, X.-G., & Geng, M.-Y. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.14 · Cited by 234
Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide
Sharma, A. K., Pavlova, S. T., Kim, J., Finkelstein, D., Hawco, N. J., Rath, N. P., Kim, J., & Mirica, L. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210588m · Cited by 225
Jang, H., Arce, F. T., Ramachandran, S., Capone, R., Azimova, R., Kagan, B. L., Nussinov, R., & Lal, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914251107 · Cited by 217
Platinum-based inhibitors of amyloid-β as therapeutic agents for Alzheimer's disease
Barnham, K. J., Kenche, V. B., Ciccotosto, G. D., Smith, D. P., Tew, D. J., Liu, X., Perez, K., Cranston, G. A., Johanssen, T. J., Volitakis, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800712105 · Cited by 209
Wang, Q., Yu, X., Patal, K., Hu, R., Chuang, S., Zhang, G., & Zheng, J. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400051e · Cited by 203
Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells
Kapitza, S., Pongratz, M., Jakupec, M. A., Heffeter, P., Berger, W., Lackinger, L., Keppler, B. K., & Marian, B. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0617-0 · Cited by 200
Lee, S., Zheng, X., Krishnamoorthy, J., Savelieff, M. G., Park, H. M., Brender, J. R., Kim, J. H., Derrick, J. S., Kochi, A., Lee, H. J., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja409801p · Cited by 182
Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease
Hayne, D. J., Lim, S., & Donnelly, P. S. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00026a · Cited by 174
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
Heffeter, P., Böck, K., Atil, B., Reza Hoda, M. A., Körner, W., Bartel, C., Jungwirth, U., Keppler, B. K., Micksche, M., Berger, W., et al. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-010-0642-1 · Cited by 173
The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity
Sharma, A. K., Pavlova, S. T., Kim, J., Kim, J., & Mirica, L. M. (2013) · Metallomics · doi:10.1039/c3mt00161j · Cited by 150
New Ruthenium Complexes for the Treatment of Cancer
Keppler, B. K., Henn, M., Juhl, U. M., Berger, M. R., Niebl, R., & Wagner, F. E. (1989) · Progress in clinical biochemistry and medicine · doi:10.1007/978-3-642-74760-1_3 · Cited by 143
Klein, W. L. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129039 · Cited by 141
Man, B. Y.-W., Chan, H., Leung, C., Chan, D. S., Bai, L., Jiang, Z., Li, H., & Ma, D. (2011) · Chemical Science · doi:10.1039/c0sc00636j · Cited by 136
Effect of Metals on Kinetic Pathways of Amyloid-β Aggregation
Hane, F. T., & Leonenko, Z. (2014) · Biomolecules · doi:10.3390/biom4010101 · Cited by 134
Kapitza, S. B., Jakupec, M. A., Uhl, M., Keppler, B. K., & Marian, B. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.002 · Cited by 119
KLEIN, A. M., KOWALL, N. W., & FERRANTE, R. J. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07845.x · Cited by 115
Valensin, D., Anzini, P., Gaggelli, E., Gaggelli, N., Tamasi, G., Cini, R., Gabbiani, C., Michelucci, E., Messori, L., Kozłowski, H., et al. (2010) · Inorganic Chemistry · doi:10.1021/ic902593e · Cited by 92
Prangkio, P., Yusko, E. C., Sept, D., Yang, J., & Mayer, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047261 · Cited by 87
Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR
Cetinbas, N. M., Webb, M. I., Dubland, J. A., & Walsby, C. J. (2009) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-009-0578-5 · Cited by 85
Self-citationTimerbaev, A. R., Rudnev, A. V., Semenova, O. P., Hartinger, C. G., & Keppler, B. K. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.03.020 · Cited by 84
Valensin, D., Gabbiani, C., & Messori, L. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.04.010 · Cited by 84
Piccioli, F., Sabatini, S., Luigi Messori, A., Orioli, P., Hartinger, C. G., & Keppler, B. K. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.002 · Cited by 83
Nuclear Translocation Uncovers the Amyloid Peptide Aβ42 as a Regulator of Gene Transcription*
Barucker, C., Harmeier, A., Weiske, J., Fauler, B., Albring, K. F., Prokop, S., Hildebrand, P., Lurz, R., Heppner, F. L., Huber, O., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.564690 · Cited by 79
Development of a Platinum Complex as an anti‐Amyloid Agent for the Therapy of Alzheimer’s Disease
Kenche, V. B., Hung, L. W., Perez, K. A., Volitakes, I., Ciccotosto, G., Kwok, J., Critch, N., Sherratt, N., Cortés, M., Lal, V., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201209885 · Cited by 77
Heffeter, P., Pongratz, M., Steiner, E., Chiba, P., Jakupec, M. A., Elbling, L., Marian, B., Körner, W., Sevelda, F., Micksche, M., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073395 · Cited by 76
Webb, M. I., Wu, B., Jang, T., Chard, R. A., Wong, E. W. Y., Wong, M. Q., Yapp, D. T. T., & Walsby, C. J. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201302671 · Cited by 72
Self-citationCollin, F., Sasaki, I., Eury, H., Faller, P., & Hureau, C. (2013) · Chemical Communications · doi:10.1039/c3cc38537j · Cited by 68
Promising in Vitro anti-Alzheimer Properties for a Ruthenium(III) Complex.
Messori, L., Camarri, M., Ferraro, T., Gabbiani, C., & Franceschini, D. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003567 · Cited by 68
Kumar, A., Moody, L., Olaivar, J. F., Lewis, N. A., Khade, R. L., Holder, A. A., Zhang, Y., & Rangachari, V. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100046m · Cited by 66
Depenbrock, H., Schmelcher, S., Peter, R., Keppler, B. K., Weirich, G., Block, T. R., Rastetter, J., & Hanauske, A.-R. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00277-3 · Cited by 54
Cebrián-Losantos, B., Reisner, E., Kowol, C. R., Roller, A., Shova, S. G., Arion, V. B., & Keppler, B. K. (2008) · Inorganic Chemistry · doi:10.1021/ic800506g · Cited by 52
Proteins Membrane Binding and Pore Formation
Anderluh, G., & Lakey, J. H. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6327-7 · Cited by 51
EPR as a probe of the intracellular speciation of ruthenium(iii) anticancer compounds
Webb, M. I., & Walsby, C. J. (2013) · Metallomics · doi:10.1039/c3mt00090g · Cited by 50
Self-citationInterference of a new cyclometallated Pt compound with Cu binding to amyloid-β peptide
Sasaki, I., Bijani, C., Mallet‐Ladeira, S., Bourdon, V., Faller, P., & Hureau, C. (2012) · Dalton Transactions · doi:10.1039/c2dt12177h · Cited by 50
Hartinger, C. G., Hann, S., Koellensperger, G., Sulyok, M., Groessl, M., Timerbaev, A. R., Rudnev, A. V., Stingeder, G. J., & Keppler, B. K. (2005) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp43583 · Cited by 47
Luo, J., Mohammed, I., Wärmländer, S. K. T. S., Hiruma, Y., Gräslund, A., & Abrahams, J. P. (2014) · Biomacromolecules · doi:10.1021/bm401874j · Cited by 38
Zhou, F., Xu, Y., & Hou, X. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23354 · Cited by 35
Kreuser, E. D., Keppler, B. K., Berdel, W. E., Piest, A., & Thiel, E. (1992) · PubMed · Cited by 34
(2010) · BioMolecular Concepts · doi:10.1515/bmc · Cited by 28
Hureau, C., & Faller, P. (2014) · Dalton Transactions · doi:10.1039/c3dt52954a · Cited by 21
Giannakopoulos, P., Bouras, C., Herrmann, F. R., Klein, W. L., Kövari, E., Savioz, A., & Giacobini, E. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.062 · Cited by 1
Research works printed but not linked: 3
- Galeano, 1992, Arzneim.-Forsch./Drug Res., 42, 821
- Kreuser, 1992, Semin. Oncol., 19, 73
- Kim, 1988, Neurosci. Res. Commun., 2, 121
Cited by
Encyclopedia of Inorganic and Bioinorganic Chemistry
(2011) · Wiley eBooks · doi:10.1002/9781119951438 · Cited by 1,585
Self-citationZhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“568 This suggests that metal-based covalent inhibitors have promising potential in AD drug development.”
BackgroundSavelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Fasae, K. D., Abolaji, A. O., Faloye, T. R., Odunsi, A. Y., Oyetayo, B. O., Enya, J. I., Rotimi, J. A., Akinyemi, R. O., Whitworth, A. J., & Aschner, M. (2021) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2021.126779 · Cited by 154
Metal complexes that bind to the amyloid-β peptide of relevance to Alzheimer’s disease
Gomes, L. M., Bataglioli, J. C., & Storr, T. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213255 · Cited by 97
Self-citation
Metadata
- Authors
- Jones, M. R., Mu, C., Wang, M. C. P., Webb, M. I., Walsby, C. J., & Storr, T.
- Affiliations
- Simon Fraser University (CA)
- Corresponding author
- Walsby, Charles J.
- Storr, Tim
- Venue
- Metallomics
- Publisher
- Oxford University Press (OUP)
- Published
- 2015
- Volume
- 7
- Issue
- 1
- Pages
- 129-135
- ISSN
- 1756-5901 (ISSN-L)
- 1756-591X
- OpenAlex
- W2071350305
- Cited by
- 50
- References
- 79
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 7 · 2023: 6 · 2022: 2 · 2021: 6 · 2020: 4 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 2
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Metallomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Natural Sciences and Engineering Research Council of Canada
- Michael Smith Foundation for Health Research
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- KP1019, ruthenium(III) complexes, amyloid-beta, amyloid-beta aggregation, Alzheimer's disease, neurotoxicity, histidine binding, neuronal viability, drug repurposing
- MeSH terms
- Alzheimer Disease, Amyloid, Cell Survival, Humans, Indazoles, Organometallic Compounds, Amyloid beta-Peptides, Ruthenium Compounds, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.